Scarica l'app Stockscreener
1.28
36.46%
0.342
Precedente Chiudi:
$0.938
Aprire:
$1.06
Volume 24 ore:
6.78M
Relative Volume:
17.42
Capitalizzazione di mercato:
$56.27M
Reddito:
-
Utile/perdita netta:
$-81.22M
Rapporto P/E:
-0.4169
EPS:
-3.07
Flusso di cassa netto:
$-74.41M
1 W Prestazione:
+32.12%
1M Prestazione:
+36.00%
6M Prestazione:
+34.23%
1 anno Prestazione:
+155.80%
Intervallo 1D:
$0.8364
$1.28
Intervallo di 1 settimana:
$0.8235
$1.28
Portata 52W:
$0.5001
$1.93
Xilio Therapeutics Inc Stock (XLO) Company Profile
Nome
Xilio Therapeutics Inc
Settore
Industria
Telefono
617-833-1027
Indirizzo
828 WINTER STREET, WALTHAM
Confronta XLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
1.28 | 56.27M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-12-21 | Iniziato | Chardan Capital Markets | Buy |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-16 | Iniziato | Cowen | Outperform |
| 2021-11-16 | Iniziato | Guggenheim | Buy |
| 2021-11-16 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-16 | Iniziato | Raymond James | Outperform |
Mostra tutto
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
Xilio Therapeutics Enters into Additional Private Placement with Gilead; Issues Securities at $25 Million Aggregate Investment - Defense World
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Canada
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com India
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics to Present Initial Phase 2 Data for - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - Yahoo Finance
Xilio Therapeutics Hires Caroline Hensley as Chief Legal Officer - Bloomberg Law
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - The Bakersfield Californian
Xilio Therapeutics, Inc. Appoints Caroline Hensley as chief legal officer - Marketscreener.com
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - MSN
Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Yahoo Finance
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World
Xilio Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Xilio Therapeutics Inc. (XLO) Quarterly 10-Q Report - Quartzy
Xilio to present new cancer treatment data at SITC - Investing.com
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - GlobeNewswire
Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan
Xilio Therapeutics to Present Initial Phase 1C Dose - GlobeNewswire
Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - GlobeNewswire Inc.
Companies Like Xilio Therapeutics (NASDAQ:XLO) Are In A Position To Invest In Growth - Simply Wall St
Xilio Therapeutics Announces Upcoming Poster Presentation - GlobeNewswire
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of - The Bakersfield Californian
Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan
XOS stock touches 52-week low at $4.62 amid market challenges - Investing.com
XBP stock plunges to 52-week low at $1.05 amid market challenges - Investing.com
XPEV: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
Xilio Therapeutics Inc (XLO) rating initates by Chardan Capital Markets - Knox Daily
Market Resilience: XTI Aerospace Inc. (XTIA) Finishes Weak at 0.22, Down -4.06 - The Dwinnex
Tencent-Backed AI Drug Researcher Xtalpi’s Shares Double On Revenue Rise - Forbes Africa
Xilio Therapeutics Inc (XLO)’s highs and lows: A closer look at its stock price fluctuations - US Post News
(XFLT) Trading Signals - Stock Traders Daily
Balance Sheet Breakdown: Xilio Therapeutics Inc (XLO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
There’s evidence fragile X symptoms can be reduced with an experimental drug - KUOW News and Information
Slew of New Drugs Sends Xencor Shares Soaring - Los Angeles Business Journal
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World
XTX Topco Ltd Has $2.01 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV) - Defense World
Xilio Therapeutics faces Nasdaq delisting over share price - Investing.com India
Xilio Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com Australia
XLO Stock Sees Decline of Approximately -10.26% in Last Five Days - Knox Daily
Analytical Lens: Exploring Xilio Therapeutics Inc (XLO)’s Financial Story Through Ratios - The Dwinnex
Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference - GlobeNewswire
Xilio Therapeutics shares hold Buy rating on clinical trial focus - Investing.com
Xilio Therapeutics shares hold Buy rating on clinical trial focus By Investing.com - Investing.com Canada
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results - GlobeNewswire
Xilio Therapeutics Inc Azioni (XLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xilio Therapeutics Inc Azioni (XLO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10% Owner |
Apr 02 '24 |
Buy |
0.76 |
485,250 |
368,790 |
7,345,473 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 08 '24 |
Sale |
0.64 |
733 |
469 |
2,019,563 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 08 '24 |
Sale |
0.64 |
267 |
171 |
734,546 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Jan 11 '24 |
Sale |
0.87 |
1,566 |
1,362 |
2,021,836 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Jan 12 '24 |
Sale |
0.83 |
1,540 |
1,278 |
2,020,296 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Jan 11 '24 |
Sale |
0.87 |
569 |
495 |
735,373 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Jan 12 '24 |
Sale |
0.83 |
560 |
465 |
734,813 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):